Document is current

Article History

Received: 29 December 2020

Accepted: 17 November 2021

First Online: 13 January 2022

Competing interests

: M.J.K. is an employee of Jacksonville Center for Clinical Research, an organization that has received research grant funds from Amgen and multiple other manufacturers of lipid-lowering agents. M.J.K. has no direct personal financial relationship with Amgen, the manufacturer of olpasiran, and is an unpaid member of the Northeast Florida AHA Board. P.M.M. reports speaker and consulting fees from Amgen and Regeneron; consulting/advisory fees and grant research support from Esperion; grant research support from Ionis, Aegerion and the FH Foundation; speaker fees from Amarin; consulting fees from Stage II Innovations/Renew and Kaneka; advisor fees from Novartis; and fees for genetic testing kits from GB Life Sciences. S.J.B. reports Scientific Advisory Board/Consultant/Speaker for Amgen; and Scientific Advisory Board/Consultant for Sanofi Regeneron, Akcea and Novartis. J.N. and M.H.-I. have nothing to disclose. H.S.W. reports research funding from Amgen and Novo Nordisk; research funding and scientific advisory fees from Novartis; and speaker fees from Esperion. S.M. and T.P. are employees of Arrowhead Pharmaceuticals and have received Arrowhead stock options. M.F., H.K., T.V., W.S., H.W., M.E.D., B.M.R., O.H. and J.H. are employees of Amgen and own Amgen stock. S.M.H. is an officer, executive and shareholder in Amgen; a scientific founder of and shareholder in Tenaya Therapeutics; and serves on the Scientific Advisory Board of the German Centre for Cardiovascular Research. G.F.W. has received honoraria for lectures or advisory boards and research grants from Sanofi, Regeneron, Amgen, Arrowhead, Novartis and Kowa.